US Neurology Editorial Board member, Stewart Tepper (Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA), discusses the latest therapies in the management of headache.
Questions
- What are the current unmet needs in new therapies for headache? (0:04)
- What is the rationale for targeting calcitonin gene-related peptide (CGRP) in the management of headache disorders? (0:45)
- What anti-CGRP monoclonal antibodies are currently available for migraine prevention and how are they administered? (1:28)
- Which patients are most likely to respond to these therapies and in which patients should they not be used? (3:08)
- What is known about the short-term safety profile of these therapies? (4:12)
- What are the possible long-term side effects of anti-CGRP monoclonal antibodies? (5:21)
Speaker disclosures:
Grants for research (no personal compensation): Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, eNeura, Neurolief, Scion Neurostim, Teva, Zosano.
Consultant and/or Advisory Boards: Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, ATI, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Cefaly, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Sudler and Hennessey, Supernus, Teva, Theranica, Trinity Partners, XOC, Zosano.
Royalties: Springer.
Salary: Dartmouth-Hitchcock Medical Center, American Headache Society.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
